Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2022
- Friday, November 18, 2022, 7:11
- PR Newswire
- Add a comment
Data from Ongoing Phase 1/2 Study of INT230-6 Alone or in Combination with Ipilimumab (INTENSITY# IT-01; BMS# CA184-592) Selected for Oral Podium Presentation Exploratory Kaplan Meier Analysis of the refractory Sarcoma Population Shows that dosing INT230-6 Equivalent to 40% or More of the…
About the Author
admin has written 21721 stories on this site.